OBJECTIVES: Our objective was to compare long-term outcomes of deep brain stimulation (DBS) of the globus pallidus interna (GPi) and subthalamic nucleus (STN) for patients with Parkinson disease (PD) in a multicenter randomized controlled trial. METHODS: Patients randomly assigned to GPi (n = 89) or STN DBS (n = 70) were followed for 36 months. The primary outcome was motor function on stimulation/off medication using the Unified Parkinson's Disease Rating Scale motor subscale. Secondary outcomes included quality of life and neurocognitive function. RESULTS:Motor function improved between baseline and 36 months for GPi (41.1 to 27.1; 95% confidence interval [CI] -16.4 to -10.8; p < 0.001) and STN (42.5 to 29.7; 95% CI -15.8 to -9.4; p < 0.001); improvements were similar between targets and stable over time (p = 0.59). Health-related quality of life improved at 6 months on all subscales (all p values significant), but improvement diminished over time. Mattis Dementia Rating Scale scores declined faster for STN than GPi patients (p = 0.01); other neurocognitive measures showed gradual decline overall. CONCLUSIONS: The beneficial effect of DBS on motor function was stable and comparable by target over 36 months. Slight declines in quality of life following initial gains and gradual decline in neurocognitive function likely reflect underlying disease progression and highlight the importance of nonmotor symptoms in determining quality of life. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that improvement of motor symptoms of PD by DBS remains stable over 3 years and does not differ by surgical target. Neurology® 2012;79:55-65.
RCT Entities:
OBJECTIVES: Our objective was to compare long-term outcomes of deep brain stimulation (DBS) of the globus pallidus interna (GPi) and subthalamic nucleus (STN) for patients with Parkinson disease (PD) in a multicenter randomized controlled trial. METHODS:Patients randomly assigned to GPi (n = 89) or STN DBS (n = 70) were followed for 36 months. The primary outcome was motor function on stimulation/off medication using the Unified Parkinson's Disease Rating Scale motor subscale. Secondary outcomes included quality of life and neurocognitive function. RESULTS: Motor function improved between baseline and 36 months for GPi (41.1 to 27.1; 95% confidence interval [CI] -16.4 to -10.8; p < 0.001) and STN (42.5 to 29.7; 95% CI -15.8 to -9.4; p < 0.001); improvements were similar between targets and stable over time (p = 0.59). Health-related quality of life improved at 6 months on all subscales (all p values significant), but improvement diminished over time. Mattis Dementia Rating Scale scores declined faster for STN than GPipatients (p = 0.01); other neurocognitive measures showed gradual decline overall. CONCLUSIONS: The beneficial effect of DBS on motor function was stable and comparable by target over 36 months. Slight declines in quality of life following initial gains and gradual decline in neurocognitive function likely reflect underlying disease progression and highlight the importance of nonmotor symptoms in determining quality of life. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that improvement of motor symptoms of PD by DBS remains stable over 3 years and does not differ by surgical target. Neurology® 2012;79:55-65.
Authors: A M Lozano; A E Lang; N Galvez-Jimenez; J Miyasaki; J Duff; W D Hutchinson; J O Dostrovsky Journal: Lancet Date: 1995-11-25 Impact factor: 79.321
Authors: Paul Krack; Alina Batir; Nadège Van Blercom; Stephan Chabardes; Valérie Fraix; Claire Ardouin; Adnan Koudsie; Patricia Dowsey Limousin; Abdelhamid Benazzouz; Jean François LeBas; Alim-Louis Benabid; Pierre Pollak Journal: N Engl J Med Date: 2003-11-13 Impact factor: 91.245
Authors: Xin Gong; Diego Mendoza-Halliday; Jonathan T Ting; Tobias Kaiser; Xuyun Sun; André M Bastos; Ralf D Wimmer; Baolin Guo; Qian Chen; Yang Zhou; Maxwell Pruner; Carolyn W-H Wu; Demian Park; Karl Deisseroth; Boaz Barak; Edward S Boyden; Earl K Miller; Michael M Halassa; Zhanyan Fu; Guoqiang Bi; Robert Desimone; Guoping Feng Journal: Neuron Date: 2020-04-29 Impact factor: 17.173
Authors: Claudio Da Cunha; Suelen L Boschen; Alexander Gómez-A; Erika K Ross; William S J Gibson; Hoon-Ki Min; Kendall H Lee; Charles D Blaha Journal: Neurosci Biobehav Rev Date: 2015-02-12 Impact factor: 8.989
Authors: Stephanie Cernera; Robert S Eisinger; Joshua K Wong; Kwo Wei David Ho; Janine Lobo Lopes; Kevin To; Samuel Carbunaru; Adolfo Ramirez-Zamora; Leonardo Almeida; Kelly D Foote; Michael S Okun; Aysegul Gunduz Journal: NPJ Parkinsons Dis Date: 2020-07-06